1. Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma
- Author
-
Mitsunobu Otsuru, Hiroshi Kurita, Nobuhiro Yamakawa, Masahiro Umeda, Masaya Okura, Tomofumi Naruse, Yoshihide Ota, Tadaaki Kirita, Masashi Sasaki, Souichi Yanamoto, Shin-ichi Yamada, Yukari Shintani, and Tatsushi Matsumura
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Time Factors ,Paclitaxel ,medicine.medical_treatment ,Cetuximab ,Neutropenia ,Drug Administration Schedule ,Japan ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Adverse effect ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,Leukopenia ,Squamous Cell Carcinoma of Head and Neck ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Rash ,Progression-Free Survival ,Regimen ,Disease Progression ,Female ,Mouth Neoplasms ,Neoplasm Recurrence, Local ,medicine.symptom ,business ,Progressive disease ,medicine.drug - Abstract
Background/aim This study was conducted to compare the efficacy and safety of the weekly cetuximab plus paclitaxel (wCmab-PTX) regimen with those of the EXTREME regimen in patients with recurrent or metastatic oral squamous cell carcinoma (R/M OSCC). Patients and methods This multicenter retrospective study involved a chart review of the clinical records of R/M OSCC patients treated with wCmab-PTX in each institution between January 2013 and December 2017. Data were collected, and the efficacy, safety, and treatment outcomes were analyzed. Results The best overall response and disease control rates were 48.4% and 61.3%, respectively. The median PFS and OS were 6 and 13 months, respectively. There was no significant difference in prognosis with or without previous platinum administration. The grade 3-4 adverse events were leukopenia (16.1%), followed by acne-like rash (12.9%), and neutropenia (9.7%). All adverse events, excluding more than grade 3 infusion reactions, were tolerable and manageable. Conclusion wCmab-PTX may be considered as a treatment option for R/M patients with OSCC that is refractory to platinum-based chemotherapy, or progressive disease after receiving chemotherapy.
- Published
- 2021